Vivos Therapeutics, Inc. is a medical technology company that concentrates on addressing sleep apnea through innovative treatment solutions. Primarily known for its proprietary systems and devices, the company offers a non-surgical approach designed to improve airway function and alleviate symptoms for patients suffering from obstructive sleep apnea (OSA), a common and often undiagnosed condition linked to various health issues. Operating at the intersection of medical devices and dental care, Vivos provides its solutions primarily to healthcare professionals, enabling them with tools and training necessary to effectively manage and treat sleep disorders. This focus on a non-invasive methodology has positioned Vivos as a notable player in the sleep disorder treatment market. Its approach not only aims to provide relief for individuals but also reduces dependency on traditional continuous positive airway pressure (CPAP) machines. Vivos Therapeutics plays a significant role in enhancing patient care within the healthcare sector by bridging the gap between dentistry and medicine, helping to raise awareness and offer alternative treatments for sleep-related breathing disorders.
Website7921 Southpark Plaza
Littleton, CO, 80120
United States
Vivos Therapeutics is implementing a restructuring plan targeting $3. 6 million in annual savings while expanding several revenue initiatives that management believes could support cash flow positivity by late 2026 or early 2027.
Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced t
Detailed price information for Vivos Therapeutics Inc (VVOS-Q) from The Globe and Mail including charting and trades.
Investors talking about VVOS also mention
What share of all stock conversation is about VVOS?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% +0 | 0% +0 | 0% +0 | 0% 0 |
Of the messages about VVOS that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 73.08% -26.92 | 73.68% -26.32 | 70.19% +5.18 | 79.26% -7.63 | ||
| Bearish | 26.92% +26.92 | 26.32% +26.32 | 29.81% -5.18 | 20.74% +7.63 |
Of the messages about VVOS that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 44.44% | 68.75% | 31.23% | 50.47% | ||
| Earnings | 5.56% | 3.13% | 1.4% | 8.98% | ||
| Analysts | 0% | 0% | 13.68% | 5.26% | ||
| Technical Analysis | 50% | 28.13% | 26.32% | 30.1% | ||
| Macro | 0% | 0% | 25.61% | 4.03% | ||
| Controversies | 0% | 0% | 1.75% | 1.15% |
Of the messages about VVOS, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 37.78% | 60.81% | 43.25% | 76.81% | ||
| Newcomers | 62.22% | 39.19% | 56.75% | 23.19% |